Form 4: LENZ Director James McCollum Receives Stock Option Grant

Director James W. McCollum was granted 22,100 stock options in LENZ Therapeutics, Inc. as part of the company's director compensation policy.

Summary

• Director James W. McCollum received a grant of 22,100 stock options on June 15, 2026.
• The options have an exercise price of $6.63 per share.
• The options are set to expire on June 15, 2036.
• The grant is subject to the company's Outside Director Compensation Policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of LENZ common stock.

Future Outlook

The options vest 100% on the earlier of June 15, 2027, or the date of the next annual meeting of stockholders, contingent upon continued service as an Outside Director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning governance with shareholder interests.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-to-mid-cap biotech firms.
• The use of a one-year cliff vesting period is a common industry standard for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon future exercise of options.
• Director: Increased financial stake in the company's performance.

Next Steps

• Vesting of options on June 15, 2027, or the next annual meeting date.

Key Dates

Keywords

LENZ Therapeutics, Form 4, Insider Trading, Stock Options, Director Compensation, Equity Grant